Xarelto patent expiration europe?

There isn’t a single “Xarelto patent expiration” date in Europe. Xarelto (rivaroxaban) is protected by multiple patent families (covering the API, salts/formulations, and manufacturing methods), plus regulatory data/market exclusivity. Expiry depends on the specific patent family and the country.

Key points:
- Multiple patent families, so there are different expiry dates by country and by patent.
- Some rivaroxaban patents have already expired in many European countries; others (especially formulation, salt, or process patents) may still be in force into the mid‑2020s depending on the jurisdiction.
- In the EU, there is regulatory data/exclusivity protection (up to about 11 years after first marketing authorization for a new active substance), which can delay generic entry even after patent expiry.

If you want precise dates, tell me:
- the European country or countries you care about, and
- whether you want the status for a specific patent family (e.g., API/composition vs. salts/formulations).

I can then outline the current status for those jurisdictions and guide you on how to look it up in Espacenet or the European Patent Register.